Anti-CD47 antibody and application thereof
The present disclosure relates to the technical field of antibody drugs, and in particular, to an anti-CD47 antibody or an antigen-binding fragment thereof, a pharmaceutical composition comprising the anti-CD47 antibody or the antigen-binding fragment thereof, and applications thereof. The anti-CD47 antibody or the antigen-binding fragment thereof has significant antitumor activity and high affinity with human CD47 protein, can eliminate the capability of SIRPa to bind to CD47 on a surface of a cell, and does not have significant hemoagglutination activity and thus can be applied to the preparation of an anti-tumor drug.
1. An anti-CD47 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein
the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of HCDR1, HCDR2 and HCDR3 are set forth in SEQ ID NOs: 4, 5 and 6, respectively, and
the light chain variable region comprises LCDR1, LCDR2 and LCDR3, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 are set forth in SEQ ID NOs: 15, 16 and 17, respectively.
2. The anti-CD47 antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody is a murine monoclonal antibody, a human-murine chimeric antibody, or a humanized antibody.
3. The CD47 antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody further comprises a heavy chain constant region of murine IgG1, IgG2, or variants thereof, and a light chain constant region of murine kappa chain or variants thereof.
4. The anti-CD47 antibody or antigen-binding fragment thereof according to claim 1 , wherein
the amino acid sequence of the heavy chain variable region is SEQ ID NO: 22, and the amino acid sequence of the light chain variable region is SEQ ID NO: 25.
5. The anti-CD47 antibody or antigen-binding fragment thereof according to claim 1 , wherein
the amino acid sequence of the heavy chain variable region is SEQ ID NO: 30, and the amino acid sequence of the light chain variable region is SEQ ID NO: 33.
6. An isolated nucleic acid encoding the anti-CD47 antibody or antigen-binding fragment thereof according to claim 1 .
7. The nucleic acid according to claim 6 , wherein
(1) the nucleotide sequence encoding the amino acid sequence of the heavy chain variable region is set forth in SEQ ID NO: 36 and
(2) the nucleotide sequence encoding the amino acid sequence of the light chain variable region is set forth in SEQ ID NO: 39.
8. A method of treating a disease comprising administering the anti-CD47 antibody or antibody-binding fragment thereof according to claim 1 to a subject in need thereof, wherein the disease is leukemia, lymphoma, breast cancer, lung cancer, gastric cancer, intestinal cancer, esophageal cancer, ovarian cancer, cervical cancer, kidney cancer, bladder cancer, pancreatic cancer, glioma and/or melanoma.